SG10202100683RA - Monoclonal antibody against melk and utilization thereof - Google Patents

Monoclonal antibody against melk and utilization thereof

Info

Publication number
SG10202100683RA
SG10202100683RA SG10202100683RA SG10202100683RA SG10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA
Authority
SG
Singapore
Prior art keywords
utilization
monoclonal antibody
antibody against
against melk
melk
Prior art date
Application number
SG10202100683RA
Inventor
Yosuke Harada
Suyoun Chung
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG10202100683RA publication Critical patent/SG10202100683RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/364Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG10202100683RA 2016-08-31 2017-08-25 Monoclonal antibody against melk and utilization thereof SG10202100683RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016169085 2016-08-31

Publications (1)

Publication Number Publication Date
SG10202100683RA true SG10202100683RA (en) 2021-03-30

Family

ID=61301839

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901435UA SG11201901435UA (en) 2016-08-31 2017-08-25 Monoclonal antibody against melk and utilization thereof
SG10202100683RA SG10202100683RA (en) 2016-08-31 2017-08-25 Monoclonal antibody against melk and utilization thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201901435UA SG11201901435UA (en) 2016-08-31 2017-08-25 Monoclonal antibody against melk and utilization thereof

Country Status (14)

Country Link
US (1) US11066477B2 (en)
EP (1) EP3508576A4 (en)
JP (1) JP7094557B2 (en)
KR (1) KR102579047B1 (en)
CN (1) CN109890963B (en)
AU (1) AU2017318907B2 (en)
BR (1) BR112019003408A2 (en)
CA (1) CA3035160A1 (en)
IL (1) IL264826B1 (en)
MX (1) MX2019002269A (en)
RU (1) RU2756982C2 (en)
SG (2) SG11201901435UA (en)
TW (1) TWI780067B (en)
WO (1) WO2018043311A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC High affinity anti-cd3 antibodies, and methods for their generation and use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP5087059B2 (en) 2001-10-31 2012-11-28 杏林製薬株式会社 Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CA2535808A1 (en) 2003-08-14 2005-02-24 Exelixis, Inc. Melks as modifiers of the rac pathway and methods of use
JP4721903B2 (en) 2004-01-29 2011-07-13 大日本住友製薬株式会社 Novel tumor antigen protein and use thereof
WO2006016525A2 (en) 2004-08-10 2006-02-16 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP2009502115A (en) 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 Diagnostic method for small cell lung cancer
WO2007058933A2 (en) 2005-11-10 2007-05-24 Exelixis, Inc. Melks as modifiers of the rho pathway and methods of use
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
WO2009131365A2 (en) * 2008-04-21 2009-10-29 한국생명공학연구원 Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer
TWI466680B (en) 2008-08-01 2015-01-01 Oncotherapy Science Inc Melk epitope peptides and vaccines containing the same
TWI485245B (en) 2010-01-25 2015-05-21 Oncotherapy Science Inc Modified melk peptides and vaccines containing the same
WO2012016082A1 (en) 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
EP2574929A1 (en) 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
TWI623536B (en) 2012-01-19 2018-05-11 腫瘤療法 科學股份有限公司 1,5-naphthyridine derivatives and melk inhibitors containing the same
RU2504785C1 (en) 2012-11-23 2014-01-20 Общество с ограниченной ответственностью "Синтавр" Diagnostic technique for breast cancer
CN104995208A (en) * 2013-01-11 2015-10-21 诺华股份有限公司 MELK regulation for the treatment of breast cancer
CN108064284A (en) 2014-12-12 2018-05-22 国立大学法人京都大学 The extremely antibody of the corner structure of 22 and 23 of specific recognition amyloid beta

Also Published As

Publication number Publication date
RU2019107355A3 (en) 2020-11-02
IL264826A (en) 2019-04-30
EP3508576A4 (en) 2020-04-22
US11066477B2 (en) 2021-07-20
TWI780067B (en) 2022-10-11
RU2019107355A (en) 2020-10-01
AU2017318907B2 (en) 2023-07-06
BR112019003408A2 (en) 2019-06-25
CN109890963A (en) 2019-06-14
MX2019002269A (en) 2019-09-18
KR20190043591A (en) 2019-04-26
JP7094557B2 (en) 2022-07-04
TW201818972A (en) 2018-06-01
JPWO2018043311A1 (en) 2019-06-24
CA3035160A1 (en) 2018-03-08
KR102579047B1 (en) 2023-09-14
AU2017318907A1 (en) 2019-03-21
SG11201901435UA (en) 2019-03-28
AU2017318907A2 (en) 2019-03-28
IL264826B1 (en) 2024-02-01
EP3508576A1 (en) 2019-07-10
CN109890963B (en) 2023-10-03
RU2756982C2 (en) 2021-10-07
US20190185575A1 (en) 2019-06-20
WO2018043311A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL290412B (en) Novel cd47 monoclonal antibodies and uses thereof
HK1259426A1 (en) Anti-pd-l1 antibodies and uses thereof
HK1255604A1 (en) Anti-pd-l1 antibodies and uses thereof
IL264011A (en) Antibodies against tim3 and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
ZA201902533B (en) Anti-pd-l1 antibodies and variants
IL262092B (en) Humanized anti-pacap antibodies and uses thereof
HK1251587A1 (en) Antibody against glypican-3 and application thereof
IL273411A (en) Anti-pd-l1 antibody and uses thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
HK1246805A1 (en) Broad-spectrum monoclonal anti-flu b antibody and uses thereof
IL263242A (en) Cytosol-penetrating antibody and use thereof
IL258924A (en) Humanized anti-dkk2 antibody and uses thereof
IL274502A (en) Anti-ox40 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof